RIGL - リジェル・ファ―マシュ―ティカルズ (Rigel Pharmaceuticals Inc.) リジェル・ファ―マシュ―ティカルズ

 RIGLのチャート


 RIGLの企業情報

symbol RIGL
会社名 Rigel Pharmaceuticals Inc (リジェル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 リジェル・ファーマシューティカルズ(Rigel Pharmaceuticals Inc.)は臨床段階のバイオ技術会社である。同社は免疫および血液学的疾患、癌および希少疾患を有する患者の生活を改善する新規小分子薬物の発見、開発および提供に従事する。同社の研究は疾患メカニズムにシグナル伝達経路に焦点を当てる。同社の製品には、持続性の免疫血小板減少症(ITP)患者の治療のための経口脾臓チロシンキナーゼ(SYK)阻害剤が含まれる。現在の臨床プログラムは、自己免疫性溶血性貧血およびIgA腎症におけるフォスタマチニブの第2相試験、インターロイキンレセプター関連キナーゼ(IRAK)プログラムに関する第I相試験を含む。さらに、BerGenBio AS、第一三共、Aclaris Therapeuticsなどのパートナーと開発候補製品を提供する。   リジェル・ファ―マシュ―ティカルズは、米国の製薬企業。炎症性・自己免疫疾患やがん、ウイルス性および代謝性の疾患領域で小分子化合物の医薬品の創薬から開発までを行う。リウマチ性関節炎、血小板減少症、喘息などの製品開発に取り組む。本社はカリフォルニア州サウスサンフランシスコ。   Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
本社所在地 1180 Veterans Blvd. South San Francisco CA 94080 USA
代表者氏名 Raul R. Rodriguez ラウル・R・ロドリゲス
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-624-1100
設立年月日 35217
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数
url www.rigel.com
nasdaq_url https://www.nasdaq.com/symbol/rigl
adr_tso
EBITDA EBITDA(百万ドル) -94.41800
終値(lastsale) 3.25
時価総額(marketcap) 540941186.5
時価総額 時価総額(百万ドル) 496.00150
売上高 売上高(百万ドル) 2.68700
企業価値(EV) 企業価値(EV)(百万ドル) 361.00950
当期純利益 当期純利益(百万ドル) -93.47300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Rigel Pharmaceuticals Inc. revenues decreased 50% to $1.8M. Net loss increased 45% to $49.9M. Revenues reflect Contract revenues from collaborations decrease from $3.6M to $0K. Higher net loss reflects General and administrative - Balancing v increase from $13.9M to $28.8M (expense) Gain on disposal of assets decrease from $732K (income) to $0K.

 RIGLのテクニカル分析


 RIGLのニュース

   Thrombopoietin Receptor Agonist Market Significantly Stepping towards the Success Till 2027| Amgen, Novartis, Rigel Pharmaceuticals  2021/08/27 12:08:28 OpenPR
Prior to the widespread availability of thrombopoietin receptor agonists (TPO-RA), splenectomy and rituximab were the most prevalent second-line therapies for patients with immunological thrombocytopenia (ITP). Both approaches have the potential to cure the disease. Long-term answers, on the other hand,
   SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL  2021/08/16 20:30:00 PR Newswire
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The
   Rigel Stock Falls After Update From COVID-19 Program  2021/08/13 12:21:15 Business Insider Markets
The FDA has informed Rigel Pharmaceuticals Inc (NASDAQ: RIGL ) that data submitted in May from fostamatinib Phase 2 trial
   Rigel : FDA Didn''t Issue EUA For Fostamatinib For Treatment Of COVID-19 In Hospitalized Adults  2021/08/13 11:54:15 Business Insider Markets
(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) said Friday that the U.S. Food and Drug Administration did not issue emergency use authorization for fostamatinib for the treatment of COVID-19 in hospitalized adults, due to insufficient clinical data. In Friday pre-market trade, RIGL was trading at $3.60, down $0.53 or 12.83%. "The FDA has
   Astounding Stock: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), ShiftPixy, Inc. (NASDAQ:PIXY)  2021/08/09 22:54:15 Stock Equity
Rigel Pharmaceuticals, Inc. (RIGL) with the stream of 1.71% also noticed, India ShiftPixy, Inc. (PIXY) encountered a rapid change of -1.37% in the last hour of Mondays trading session. Rigel The post Astounding Stock: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), ShiftPixy, Inc. (NASDAQ:PIXY) appeared first on Stocks Equity .
   Rigel Pharmaceuticals (RIGL) EHA Investor Presentations - Slideshow  2021/06/18 22:12:35 Seeking Alpha
   Rigel to Present at the Jefferies Virtual Healthcare Conference  2021/05/26 00:00:00 BioSpace
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company''s president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:00 p.m. Eastern Time .
   Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Surging 112% in 2021, Outlook Strong  2021/05/17 13:00:00 Stocks Register
The trading price of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) closed higher on Friday, May 14, closing at $3.62, 2.49% higher than its previous close. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Traders who pay close attention to intraday price movement should know that it fluctuated between Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Surging 112% in 2021, Outlook Strong Read More »
   A Recommendation For Rigel Pharmaceuticals  2021/05/16 14:42:22 Seeking Alpha
   Als in een waar jongensboek ontrafelden zij een groot coronamysterie  2021/05/12 18:57:00 Nederlands Dagblad
Wetenschappers aan het Amsterdam UMC hebben een raadsel ontcijferd waarover artsen zich wereldwijd het hoofd breken: waarom verslechtert de situatie van de ene coronapatiënt na een dag of tien acuut, en van de ander niet? Hun antwoord: de productie van antistoffen met een afwijkende vorm laat de afweercellen in de longen op tilt slaan.AmsterdamHun onderzoek heeft veel weg van een jongensboek, zegt Menno de Winther, hoogleraar vasculaire immunologische celbiologie aan het Amsterdam UMC.Een grote groep enthousiaste artsen en promovendi ziet in het lab de ene na de andere hypothese bevestigd. Vervolgens pikt een Amerikaans biotechbedrijf de eerste resultaten op en zet een grote klinische studie in gang. En nu, amper een jaar na aanvang, staan hun bevindingen in het vakblad Science Translational Medicine.Het is een voorbeeld van goede samenwerking tussen wetenschap en de farmaceutische industrie, zegt hoogleraar immunologie Huub Savelkoul (Wageningen Universiteit), die zelf niet betrokken is bij het onderzoek.observatiesDe onderzoekers raakten aan het begin van de coronapandemie gefascineerd door observaties van longartsen.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リジェル・ファ―マシュ―ティカルズ RIGL Rigel Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)